

# Charles L. Clark III, M.D.

Abilene, TX 79606

## Employment

---

- May 2017-Present      **Integrated Clinical Research, LLC – Retina Research Institute of Texas** in Abilene, TX – Research Investigator
- May 2017-Present      **Ophthalmology Specialist of Texas, PLLC dba/West Texas Retina Consultants** located at 5441 Health Center Drive Abilene, TX
- 2014-May 2017      **Retina Specialty Institute:** Central Florida offices in Gainesville, The Villages, and Inverness
- 2014-2017      **Hospital Affiliations:** North Florida Regional Medical center, Citrus Memorial Hospital

## Education

---

- 2014      **Ophthalmology Board certification**
- 2012-2014      **Vitreoretinal Fellowship**
- Retina Specialists of Alabama/University of Alabama at Birmingham (Robert Morris/C Douglas Witherspoon)
- 2009-2012      **Ophthalmology Residency**
- Shands/University of Florida, Gainesville, FL
- 2008-2009      **Internal Medicine Internship**
- Orlando Regional Medical Center, Orlando, FL
- 2004-2008      **Medical Education**
- Florida State University College of Medicine, Tallahassee, FL, May 2008 (Alpha Omega Alpha member)
- 1999-2003      **Undergraduate Education**
- University of Florida, Gainesville, FL, BS in Microbiology and Cell Science (**Summa Cum Laude**, minor in Classical Studies), December 2003

## Research Positions

---

- May 2017-Present      **Research Investigator - Integrated Clinical Research, LLC, Abilene TX**
- Future Studies
- Summer, 2005      **Graduate Laboratory Research Assistant – University of Florida, Dept. of Ophthalmology, Gainesville, FL**
- **Independent Research** – Investigation of neurodegenerative diseases related to misfolded proteins with primary emphasis on retinitis pigmentosa  
Principle Investigator - Shalesh Kaushal, M.D., Ph.D.
- 2003-2004      **Undergraduate Laboratory Research Assistant – University of Florida, Dept. of Ophthalmology, Gainesville, FL**
- **Independent Research** – Investigation of neurodegenerative diseases related to misfolded proteins with primary emphasis on retinitis pigmentosa  
Principle Investigator – S. Kaushal, M.D., Ph.D.

## Publications & Authorships

---

### Published Manuscript

*Robert E. Morris, Charles L. Clark III, Mathew R., Matthew H. Oltmanns, Ferenc Kuhn. Endophthalmitis. Chapter 72 or Master Techniques in Ophthalmic Surgery. Debuted 2013 AAO meeting.*

*CLC 2/10/18*

*Ohlstein DH, Hooten C, Perez J, Clark CL 3<sup>rd</sup>, Samy H.* Orbital aspergillosis: voriconazole – the new standard treatment? *Case Rep Ophthalmol.* 2012 Jan; 3 (1): 46-53.

*Knape RM, Motamarry SP, Clark CL 3<sup>rd</sup>, Bohsali KI, Khuddus N.* Morning glory disc anomaly and optic nerve coloboma. *Clin Pediatr (Phila).* 2011 May 27.

*R.M. Knape, E. Zavaleta, C.L. Clark III, M.C. Peden.* Intravitreal Bevacizumab Treatment of Bilateral Peripapillary Choroidal Neovascularization from Optic Nerve Head Drusen in a Child. *Journal of the American Association for Pediatric Ophthalmology and Strabismus.* 2011 Feb;15(1):87-90.

*M.P. Krebs, D.C. Holden, P. Joshi, C.L. Clark 3<sup>rd</sup>, A.H. Lee, S.Kaushal.* Molecular Mechanisms of Rhodopsin Retinitis Pigmentosa and the Efficacy of Pharmacological Rescue. *J Mol Biol.* 2010 Feb 5; 395(5): 1063-1078.

### Presentations

Workplace Eye Injury: present to the American Association for Civil Engineers at UAB Callahan Eye Hospital on 11/21/13.

Retinal Resident Lectures: Eye trauma, Diabetes, Inherited Retinal Dystrophies 2012-2014

**C.L.Clark III**, M Sherwood. Effect of Diabetic Retinopathy and Panretinal Photocoagulation on Retinal Nerve Fiber Layer Thickness. Annual Resident Research Day University of Florida 2012.

**C.L. Clark 3<sup>rd</sup>**, *S.Kaushal.* Molecular Mechanisms of Rhodopsin Retinitis Pigmentosa and the Efficacy of Pharmacological Rescue. Florida Society of Ophthalmology Annual Meeting 2010.

*M.P. Krebs, S.M. Noorwez, C.L. Clark, R.Malhotra, S.Kaushal.* Thermal Stability of Pharmacologically-Rescued Mutant Rhodopsins Correlates With Their Autosomal Dominant Retinitis Pigmentosa Phenotype. Association for Research in Vision and Ophthalmology (ARVO) Presentation – May 2005.

### Honors Senior Thesis (Summa cum laude)

**C.L. Clark.** Studies of Misfolded Proteins Associated with Inherited Human Disease: Retinitis Pigmentosa. Advisor: S. Kaushal –December 2003.

### College of Agricultural and Life Sciences Honors Program Requirement

The 2003 University of Florida Undergraduate Strategic Plan. Advisor: E. Jane Luzar – Submitted and presented to the University President Charles Young and committee May 2003.

### Leadership Position

---

2005-2008      **Curriculum Chair**, Florida State University College of Medicine Class of 2008

### Honors & Awards

---

2010            **Florida Society of Ophthalmology, Resident Research Day, Orlando, FL**  
                   • Second place

2006-2007    **Florida State University, Tallahassee, FL**  
                   • Junior Clerkship Honors – Surgery, Internal Medicine, OB/GYN, Psychiatry, Family Medicine, Doctoring

2004-2005    **Florida State University, Tallahassee, FL**  
                   • Sports Medicine Scholar

2003-2004    **University of Florida, Gainesville, FL**  
                   • Superior Virology Student Award – Highest grade in graduate General Virology

- 2001-2003 **University of Florida, Gainesville, FL**
  - President’s Honor Roll and Dean’s list
- 2001-2003 **University of Florida, Gainesville, FL**
  - College of Agricultural and Life Sciences upper division honors program
- 2002 **University of Florida, Gainesville, FL**
  - National Society of Collegiate Scholars – National scholastic achievement inductee
- 2002 **University of Florida, Gainesville, FL**
  - Golden Key National Honor Society – National scholastic achievement inductee
- 1999-2003 **University of Florida, Gainesville, FL**
  - Florida Bright Futures Scholarship
- 1999 **Dr. Phillips High School, Orlando, FL**
  - Valedictorian (Class of 850)

**Community Service/ Extracurricular Activities**

---

- Present Avid cook, golfer, oenophile
- 2007 **Project Homeless Connect, Orlando, FL – Volunteer**
- 2005-2006 **FSU Rural Medicine Interest Group, Tallahassee, FL – Hospitality Chairman**
- 2004-2006 **FSUCares, 5K Fundraiser & Race, Tallahassee, FL – Volunteer**
- 2004-2006 **Intramural Sports, Tallahassee, FL – Captain of softball team**
- 2001-2004 **Eye Center at Shands Hospital, Gainesville, FL – Volunteer**
- 2000-2001 **Metcalf Elementary School, Gainesville, FL – Mentor for underprivileged children**

**Research Studies**

---

- 2017 – Present **Sub-Investigator. Allergan CEDAR 150998-005, Safety and Efficacy of Abicipar Pegol(AGN150998) in Patients with Neovascular Age-Related Macular Degeneration.**  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: S Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.
- 2017 – 2018 **Sub-Investigator. F.Hoffmann-La Roche, Spectri GX29185, A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographical Atrophy Secondary to Age-Related Macular Degeneration.**  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.
- 2017 – 2018 **Sub-Investigator. Alcon RTH258-C001, A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in subjects with Neovascular Age-Related Macular Degeneration.**  
Principal Investigator: Grant P. Janzen, M.D.  
Sub-Investigator: Sunil S. Patel, M.D., Ph.D., S.Young Lee, M.D., Eric Zavaleta, M.D

- 2017 – Present      Sub-Investigator. **Ophthotech Zimura OPH2003**, A Phase II/III randomized, double masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura (Anti-C5 Aptamer) in subjects with Geographic Atrophy secondary to Dry Age-Related Macular Degeneration.  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.
- 2017 – 2018      Sub-Investigator. **Genentech Avenue BP29647**, A multi-center, multiple-dose and regimen, randomized, active comparator controlled, double-masked, parallel group, 36-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with Choroidal Neovascularization secondary to Age-Related Macular Degeneration.  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., S. Young Lee, M.D., Eric Zavaleta, M.D.
- 2017 – 2018      Sub-Investigator. **Genentech Stairway CR39521**, Stairway: Simultaneous blockade of Angiopoietin-2 and VEGF with the bispecific antibody RO6867461 (RG7716) for extended durability in the treatment of Neovascular Age-Related Macular Degeneration.  
Principal Investigator: Sunil S. Patel, M.D. Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., S. Young Lee, M.D., Eric Zavaleta, M.D.
- 2017 – Present      Sub-Investigator. **Ora Graybug GBV-102-001**, A Phase 1 / 2 Multicenter Study Evaluating the Safety, Tolerability and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects with Neovascular Age-related Macular Degeneration.  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., S. Young Lee, M.D., Eric Zavaleta, M.D.
- 2018 – Present      Sub-Investigator. **Ora Kalvista KVD001-201**, A randomized sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kallikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti vascular endothelial growth factor (VEGF)  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., S. Young Lee, M.D., Eric Zavaleta, M.D.
- 2018 – Present      Sub-Investigator. **ThromboGenics THR-149-001**, A multi-center study under protocol entitled A Phase I, open-label, multicenter, dose escalation study to evaluate the safety of a single intravitreal injections of THR-149 for the treatment of Diabetic Macular Edema (DME)  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., S. Young Lee, M.D., Eric Zavaleta, M.D.

- 2018 – Present      Sub-Investigator. **Boehringer Ingelheim Pharmaceuticals, Inc. Robin 1386.12**, A randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 without center-involved Diabetic Macular Edema.  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., S. Young Lee, M.D., Eric Zavaleta, M.D.
- 2018 – Present      Sub-Investigator. **Trial Runners Aerpio AKB-9778**, Phase 2 double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15MG once daily or 15 MG twice daily for 12 months in patients with moderate to severe Non-Proliferative Diabetic Retinopathy.  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., S. Young Lee, M.D., Eric Zavaleta, M.D.
- 2018 – Present      Sub-Investigator. **Samsung SB11-G31-AMD**, A Phase II randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 (proposed ranibizumab biosimilar) and Lucentis in subjects with Neovascular Age-Related Macular Degeneration.  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., S. Young Lee, M.D., Eric Zavaleta, M.D.
- 2018 – Present      Sub-Investigator. **Clearside Tybee CLS1004-201**, Tybee: randomized, double masked, controlled study comparing the safety and efficacy of suprachoroidal CLS-TA with intravitreal aflibercept versus aflibercept alone in subjects with Diabetic Macular Edema  
Principal Investigator: Eric Zavaleta, M.D.  
Sub-Investigator: Sunil S. Patel, M.D., Ph.D., Grant P. Janzen, M.D., S. Young Lee, M.D.
- 2018 – Present      Sub-Investigator. **Clearside Sapphire CLS1003-301**, A randomized, masked, controlled study the safety and efficacy of suprachoroidal CLS-TA in conjunction with Intravitreal Aflibercept in the subjects with Retinal Vein Occlusion.  
Principal Investigator: Eric Zavaleta, M.D.  
Sub-Investigator: Sunil S. Patel, M.D., Ph.D., Grant P. Janzen, M.D., S. Young Lee, M.D.
- 2017 – Present      Sub-Investigator. **Ophthotech Zimura OPH2007**, A phase 2a open-label trail to assess the safety of Zimura (Anti-C5) administered in combination with Lucentis 0.5mg in treatment naïve subjects with Neovascular Age Related Macular Degeneration.  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D., Eric Zavaleta, M.D.

- 2018 – Present      Sub-Investigator. Opthea Ltd. 302-1002 WetAMD, A dose ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in patients with Neovascular Age-Related Macular Degeneration (Wet AMD)  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., Eric Zavaleta, M.D., S. Young Lee, M.D.
- 2018 – Present      Sub-Investigator. Opthea Ltd. 302-1003 DME, Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent Central-Involved Diabetic Macular Edema  
Principal Investigator: Sunil S. Patel, M.D., Ph.D.  
Sub-Investigator: Grant P. Janzen, M.D., Eric Zavaleta, M.D., S. Young Lee, M.D.
- 2018 – Present      Sub-Investigator. InSite Vision, Inc. C-12-305-001, A Phase 3, multicenter, randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of ISV-305 (0.1% Dexamethasone) compared to vehicle in the treatment of subjects with Blepharitis  
Principal Investigator: Eric Zavaleta, M.D.  
Sub-Investigator: Sunil S. Patel, M.D., Ph.D., Grant P. Janzen, M.D., S. Young Lee, M.D.